Investor mix
5 investors on record; lead investors include Versant Ventures, Celgene; 1 has since exited.
| Investor type | Count | Share |
|---|---|---|
| Venture capital | 4 | 80% |
| Other / undisclosed | 1 | 20% |
Developing antibody therapeutics for cancer and fibrosis
5 investors on record; lead investors include Versant Ventures, Celgene; 1 has since exited.
| Investor type | Count | Share |
|---|---|---|
| Venture capital | 4 | 80% |
| Other / undisclosed | 1 | 20% |